Drug:
Reaction: MYELOSUPPRESSION
20250101 - 20251231
No. 201 - 300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 201 | 25106634 |
CN |
83 | 1 |
Myelosuppression, |
||||
CETUXIMAB, IRINOTECAN HYDROCHLORIDE, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 202 | 25106635 |
CN |
71 | 1 |
Myelosuppression, |
||||
CETUXIMAB, IRINOTECAN HYDROCHLORIDE, |
||||
| 203 | 25106721 |
GB |
||
Myelosuppression, Foetal growth restriction, Foetal exposure during pregnancy, Off label use, |
||||
HUMAN IMMUNOGLOBULIN G, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, METHYLPREDNISOLONE, ANAKINRA, |
||||
| 204 | 25106726 |
GB |
||
Myelosuppression, Foetal growth restriction, Foetal exposure during pregnancy, Off label use, |
||||
HUMAN IMMUNOGLOBULIN G, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, METHYLPREDNISOLONE, ANAKINRA, |
||||
| 205 | 25106776 |
CN |
78 | 2 |
Abdominal pain, Myelosuppression, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, RITUXIMAB, RITUXIMAB, EPIRUBICIN HYDROCHLORIDE, VINCRISTINE SULFATE, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 206 | 25106864 |
CN |
68 | 1 |
Myelosuppression, |
||||
CARFILZOMIB, |
||||
| 207 | 25106988 |
GB |
1 | |
Myelosuppression, Hyperthyroidism, Off label use, |
||||
CEMIPLIMAB-RWLC, CEMIPLIMAB-RWLC, DAROLUTAMIDE, |
||||
| 208 | 25107164 |
CN |
54 | 1 |
Myelosuppression, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 209 | 25107596 |
CN |
72 | 1 |
Myelosuppression, Off label use, |
||||
OBINUTUZUMAB, |
||||
| 210 | 25107607 |
CN |
67 | 2 |
Myelosuppression, |
||||
BEVACIZUMAB, CARBOPLATIN, PACLITAXEL, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, DEXTROSE MONOHYDRATE, DEXTROSE, |
||||
| 211 | 25097252 |
CN |
70 | 2 |
Myelosuppression, |
||||
DARATUMUMAB, CARFILZOMIB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, POMALIDOMIDE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 212 | 25097341 |
CN |
66 | |
Myelosuppression, |
||||
CISPLATIN, CISPLATIN, CISPLATIN, CISPLATIN, |
||||
| 213 | 25097343 |
CN |
58 | |
Myelosuppression, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 214 | 25097354 |
CN |
70 | |
Myelosuppression, Decreased appetite, Diarrhoea, Cough, |
||||
PACLITAXEL, PACLITAXEL, |
||||
| 215 | 25097392 |
CN |
62 | 1 |
Myelosuppression, |
||||
FRUQUINTINIB, |
||||
| 216 | 25097595 |
CN |
62 | |
Myelosuppression, |
||||
OXALIPLATIN, OXALIPLATIN, |
||||
| 217 | 25097635 |
CN |
46 | |
Myelosuppression, |
||||
CISPLATIN, CISPLATIN, CISPLATIN, CISPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, |
||||
| 218 | 25097639 |
CN |
62 | |
Myelosuppression, |
||||
CISPLATIN, CISPLATIN, CISPLATIN, CISPLATIN, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, FLUOROURACIL, FLUOROURACIL, |
||||
| 219 | 25097656 |
IN |
2 | |
Leukopenia, Diarrhoea, Hypokalaemia, Hypocalcaemia, Hypomagnesaemia, Myelosuppression, Pancytopenia, Thrombocytopenia, Metabolic alkalosis, Metabolic acidosis, |
||||
LEUCOVORIN CALCIUM, FLUOROURACIL, OXALIPLATIN, |
||||
| 220 | 25097745 |
CN |
33 | |
Myelosuppression, |
||||
CISPLATIN, DOCETAXEL, DOCETAXEL ANHYDROUS, FLUOROURACIL, |
||||
| 221 | 25097746 |
CN |
68 | |
Myelosuppression, Pyrexia, |
||||
CISPLATIN, CISPLATIN, CISPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 222 | 25097751 |
CN |
57 | |
Myelosuppression, |
||||
CISPLATIN, CISPLATIN, CISPLATIN, CISPLATIN, IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 223 | 25097756 |
CN |
48 | |
Myelosuppression, |
||||
| 224 | 25097758 |
CN |
||
Myelosuppression, |
||||
BEVACIZUMAB, PEMETREXED, PEMETREXED DISODIUM, CARBOPLATIN, |
||||
| 225 | 25097877 |
US |
78 | 1 |
Delirium, Dementia, Toxicity to various agents, Oral pain, Bacteraemia, Myelosuppression, Mucosal inflammation, Dermatitis, Diarrhoea, Dysphagia, |
||||
CAPECITABINE, CLOPIDOGREL, CLOPIDOGREL BISULFATE, CLOTRIMAZOLE, DRS. CLOTRIMAZOLE, FAMILY WELLNESS CLOTRIMAZOLE, CLOTRIMAZOLE TOPICAL, MEMANTINE, MEMANTINE HYDROCHLORIDE, TIMOLOL, |
||||
| 226 | 25097946 |
US |
2 | |
Febrile neutropenia, Myelosuppression, Product use in unapproved indication, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, ETOPOSIDE, |
||||
| 227 | 25098110 |
CN |
48 | |
Myelosuppression, |
||||
CARBOPLATIN, CARBOPLATIN, PACLITAXEL, PACLITAXEL, |
||||
| 228 | 25098115 |
CN |
44 | |
Myelosuppression, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, |
||||
| 229 | 25098147 |
CN |
63 | |
Myelosuppression, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 230 | 25098175 |
CN |
62 | |
Myelosuppression, |
||||
PACLITAXEL, PACLITAXEL, PACLITAXEL, BEVACIZUMAB, BEVACIZUMAB, BEVACIZUMAB, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 231 | 25098198 |
CN |
64 | |
Myelosuppression, |
||||
CAPECITABINE, CAPECITABINE, PACLITAXEL, PACLITAXEL, |
||||
| 232 | 25098417 |
CN |
51 | 2 |
Myelosuppression, |
||||
TRASTUZUMAB, LETROZOLE, LETROZOLE TABLETS, LEUPROLIDE ACETATE, |
||||
| 233 | 25098461 |
CN |
59 | 1 |
Myelosuppression, White blood cell count decreased, Neutrophil count decreased, |
||||
PERTUZUMAB, DOCETAXEL, DOCETAXEL ANHYDROUS, TRASTUZUMAB, TRASTUZUMAB, |
||||
| 234 | 25098544 |
66 | 1 | |
Myelosuppression, Neurotoxicity, |
||||
DEXAMETHASONE, DEXAMETHASONE 1.5 MG, RITUXIMAB, CYTARABINE, OXALIPLATIN, |
||||
| 235 | 25098924 |
CN |
71 | 2 |
Myelosuppression, Neutrophil count decreased, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 236 | 25099018 |
US |
1 | |
Device related infection, Myelosuppression, Product use in unapproved indication, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, ETOPOSIDE, |
||||
| 237 | 25099019 |
US |
1 | |
Febrile neutropenia, Malignant neoplasm progression, Myelosuppression, Thrombocytopenia, Drug ineffective for unapproved indication, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, ETOPOSIDE, |
||||
| 238 | 25099166 |
US |
69 | 2 |
Myelosuppression, Device related infection, Off label use, |
||||
ETOPOSIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, |
||||
| 239 | 25099167 |
US |
53 | 2 |
Septic shock, Sepsis, Myelosuppression, Febrile neutropenia, Infection, Off label use, |
||||
ETOPOSIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, |
||||
| 240 | 25099168 |
US |
210 | 1 |
Myelosuppression, Febrile neutropenia, Infection, Off label use, |
||||
ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, |
||||
| 241 | 25099379 |
US |
2 | |
Febrile neutropenia, Sepsis, Myelosuppression, Product use in unapproved indication, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, ETOPOSIDE, |
||||
| 242 | 25099555 |
US |
65 | 1 |
Myelosuppression, Device related infection, Off label use, |
||||
ETOPOSIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, |
||||
| 243 | 25099689 |
US |
2 | |
Device related infection, Myelosuppression, Product use in unapproved indication, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, ETOPOSIDE, |
||||
| 244 | 25099696 |
US |
1 | |
Hyponatraemia, Seizure, Myelosuppression, Product use in unapproved indication, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, ETOPOSIDE, |
||||
| 245 | 25099721 |
CN |
46 | 2 |
White blood cell count decreased, Myelosuppression, |
||||
TRASTUZUMAB, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 246 | 25100356 |
CN |
14 | 1 |
Myelosuppression, Off label use, |
||||
IFOSFAMIDE, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 247 | 25100520 |
CN |
76 | 2 |
Myelosuppression, Off label use, |
||||
ABEMACICLIB, |
||||
| 248 | 25100633 |
US |
1 | |
Febrile neutropenia, Myelosuppression, Product use in unapproved indication, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, ETOPOSIDE, |
||||
| 249 | 25100636 |
US |
1 | |
Febrile neutropenia, Sepsis, Myelosuppression, Product use in unapproved indication, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, ETOPOSIDE, |
||||
| 250 | 25100674 |
CN |
71 | 2 |
Myelosuppression, |
||||
| 251 | 25100806 |
CN |
64 | 2 |
Myelosuppression, |
||||
DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT), |
||||
| 252 | 25101056 |
CN |
61 | 2 |
Myelosuppression, |
||||
| 253 | 25101058 |
US |
1 | |
Febrile neutropenia, Myelosuppression, Product use in unapproved indication, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, ETOPOSIDE, |
||||
| 254 | 25101088 |
CN |
50 | 2 |
Myelosuppression, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, DEXTROSE MONOHYDRATE, DEXTROSE, |
||||
| 255 | 25101100 |
CN |
45 | 2 |
Myelosuppression, Food aversion, Epistaxis, Nausea, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, WATER, STERILE WATER, STERILE WATER FOR INJECTION, DEXTROSE MONOHYDRATE, DEXTROSE, |
||||
| 256 | 25101101 |
CN |
65 | 2 |
Myelosuppression, |
||||
| 257 | 25101112 |
CN |
35 | 2 |
Myelosuppression, |
||||
SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 258 | 25101117 |
CN |
55 | 2 |
Myelosuppression, |
||||
| 259 | 25101195 |
CN |
||
Myelosuppression, |
||||
| 260 | 25101200 |
JP |
71 | 2 |
Myelosuppression, Myocardial infarction, Cardiac failure, Electrolyte imbalance, Diarrhoea, Drug interaction, Off label use, |
||||
CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, APIXABAN, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, CYCLOSPORINE, PACLITAXEL, PACLITAXEL, PACLITAXEL, PACLITAXEL, PACLITAXEL, |
||||
| 261 | 25101221 |
CN |
||
Myelosuppression, |
||||
PACLITAXEL, PACLITAXEL, |
||||
| 262 | 25101326 |
CN |
26 | 1 |
Myelosuppression, |
||||
IFOSFAMIDE, IFOSFAMIDE, DEXTROSE MONOHYDRATE, DEXTROSE, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, WATER, STERILE WATER, STERILE WATER FOR INJECTION, |
||||
| 263 | 25101452 |
CN |
79 | 1 |
Myelosuppression, |
||||
BICALUTAMIDE, GOSERELIN, |
||||
| 264 | 25101566 |
CN |
55 | 1 |
Myelosuppression, Platelet count decreased, |
||||
VENETOCLAX, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 265 | 25101774 |
JP |
78 | 2 |
Liver disorder, COVID-19, Myelosuppression, Platelet count decreased, Neutrophil count decreased, Product use issue, |
||||
REGORAFENIB, REGORAFENIB, AMLODIPINE, CLOPIDOGREL, CLOPIDOGREL BISULFATE, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, SOLIFENACIN SUCCIATE, SOLIFENACIN SUCCINATE, VIBEGRON, |
||||
| 266 | 25092224 |
CN |
70 | |
Myelosuppression, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, |
||||
| 267 | 25092265 |
CN |
61 | 1 |
Myelosuppression, |
||||
CARFILZOMIB, POMALIDOMIDE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 268 | 25092291 |
CN |
70 | |
Myelosuppression, Myocardial necrosis marker increased, Troponin I abnormal, |
||||
| 269 | 25092330 |
CN |
78 | |
Myelosuppression, |
||||
ETOPOSIDE, ETOPOSIDE, CARBOPLATIN, CARBOPLATIN, |
||||
| 270 | 25092390 |
CN |
58 | 2 |
Myelosuppression, Decreased appetite, Nausea, Therapy partial responder, Product use in unapproved indication, |
||||
DEXAMETHASONE SODIUM PHOSPHATE, SELINEXOR, BORTEZOMIB FOR INJECTION, BORTEZOMIB, LENALIDOMIDE, PALONOSETRON, PALONOSETRON HYDROCHLORIDE, OLANZAPINE, |
||||
| 271 | 25092399 |
NL |
||
Systemic toxicity, Thrombocytopenia, Myelosuppression, Angina pectoris, Neutropenia, Leukopenia, Nausea, Vomiting, Mucosal inflammation, Anaemia, Diarrhoea, Haematotoxicity, Gastrointestinal toxicity, Dysgeusia, Epistaxis, Fatigue, |
||||
PANITUMUMAB, BEVACIZUMAB, FLUOROURACIL, OXALIPLATIN, CAPECITABINE, |
||||
| 272 | 25092407 |
CN |
66 | 1 |
Myelosuppression, Pyrexia, Product use in unapproved indication, |
||||
DEXAMETHASONE SODIUM PHOSPHATE, SELINEXOR, BORTEZOMIB FOR INJECTION, BORTEZOMIB, LENALIDOMIDE, PALONOSETRON, PALONOSETRON HYDROCHLORIDE, OLANZAPINE, |
||||
| 273 | 25092455 |
CN |
55 | 2 |
Myelosuppression, Fatigue, Product use in unapproved indication, |
||||
DEXAMETHASONE SODIUM PHOSPHATE, SELINEXOR, BORTEZOMIB FOR INJECTION, BORTEZOMIB, LENALIDOMIDE, PALONOSETRON, PALONOSETRON HYDROCHLORIDE, OLANZAPINE, |
||||
| 274 | 25092508 |
CN |
77 | |
Myelosuppression, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, |
||||
| 275 | 25092554 |
CN |
71 | |
Myelosuppression, Rash erythematous, Epistaxis, |
||||
CISPLATIN, CISPLATIN, PACLITAXEL, PACLITAXEL, PACLITAXEL, PACLITAXEL, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, CARBOPLATIN, CARBOPLATIN, |
||||
| 276 | 25092655 |
CN |
68 | 2 |
Myelosuppression, Abdominal pain, Product use in unapproved indication, |
||||
DEXAMETHASONE SODIUM PHOSPHATE, SELINEXOR, BORTEZOMIB FOR INJECTION, BORTEZOMIB, LENALIDOMIDE, PALONOSETRON, PALONOSETRON HYDROCHLORIDE, OLANZAPINE, |
||||
| 277 | 25092710 |
CN |
63 | 1 |
Myelosuppression, Therapy partial responder, Product use in unapproved indication, |
||||
DEXAMETHASONE SODIUM PHOSPHATE, SELINEXOR, BORTEZOMIB FOR INJECTION, BORTEZOMIB, LENALIDOMIDE, PALONOSETRON, PALONOSETRON HYDROCHLORIDE, OLANZAPINE, |
||||
| 278 | 25093057 |
CN |
75 | |
Myelosuppression, Cough, Productive cough, |
||||
CISPLATIN, CISPLATIN, CISPLATIN, CISPLATIN, ETOPOSIDE, ETOPOSIDE, |
||||
| 279 | 25093299 |
CN |
70 | 2 |
Myelosuppression, |
||||
TRASTUZUMAB, ERIBULIN MESYLATE, |
||||
| 280 | 25093316 |
CN |
41 | 2 |
Myelosuppression, |
||||
PERTUZUMAB, PERTUZUMAB, TRASTUZUMAB, TRASTUZUMAB, CARBOPLATIN, CARBOPLATIN, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, |
||||
| 281 | 25093351 |
CN |
68 | 2 |
Myelosuppression, |
||||
PERTUZUMAB, TRASTUZUMAB, DOCETAXEL, DOCETAXEL ANHYDROUS, |
||||
| 282 | 25094219 |
CN |
54 | 2 |
Myelosuppression, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, TRASTUZUMAB, PERTUZUMAB, CARBOPLATIN, DOCETAXEL, DOCETAXEL ANHYDROUS, PERTUZUMAB, CARBOPLATIN, |
||||
| 283 | 25094233 |
CN |
7 | 1 |
Myelosuppression, Diarrhoea, White blood cell count decreased, |
||||
FLUOROURACIL, OXALIPLATIN, PACLITAXEL, FLUOROURACIL, PACLITAXEL, OXALIPLATIN, |
||||
| 284 | 25094263 |
CN |
61 | 2 |
White blood cell count decreased, Myelosuppression, |
||||
PAZOPANIB, PAZOPANIB HYDROCHLORIDE, PAZOPANIB, PAZOPANIB HYDROCHLORIDE, |
||||
| 285 | 25094541 |
CZ |
66 | 1 |
Neurotoxicity, Myelosuppression, Product use in unapproved indication, |
||||
OXALIPLATIN, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, DEXAMETHASONE SODIUM PHOSPHATE, RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISONE, ETOPOSIDE, CYTARABINE, |
||||
| 286 | 25094575 |
CN |
55 | 2 |
White blood cell count decreased, Myelosuppression, |
||||
PAZOPANIB, PAZOPANIB HYDROCHLORIDE, |
||||
| 287 | 25094616 |
CN |
4 | 1 |
Liver injury, Myelosuppression, |
||||
CYTARABINE, MERCAPTOPURINE, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 288 | 25094747 |
CN |
49 | 2 |
Myelosuppression, |
||||
DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT), |
||||
| 289 | 25094998 |
CN |
55 | 2 |
Hyperkalaemia, Leukopenia, Thrombocytopenia, Anaemia, Neutropenia, Myelosuppression, Hyperphosphataemia, Hypoalbuminaemia, Hypomagnesaemia, Hypophosphataemia, Infection, Rash, Blood creatinine increased, Product use in unapproved indication, |
||||
CARBOPLATIN, CARBOPLATIN, CISPLATIN, CISPLATIN, BEVACIZUMAB, |
||||
| 290 | 25095023 |
CN |
45 | 2 |
Myelosuppression, |
||||
EXEMESTANE, EXEMESTANE, |
||||
| 291 | 25095383 |
CN |
68 | 2 |
Myelosuppression, Hyponatraemia, Altered state of consciousness, Dysarthria, Product use in unapproved indication, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, CISPLATIN, CISPLATIN, |
||||
| 292 | 25095456 |
CN |
||
Myelosuppression, |
||||
GEMCITABINE HYDROCHLORIDE, CISPLATIN, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 293 | 25095702 |
US |
79 | 2 |
Myelosuppression, Thrombocytopenia, Anaemia, |
||||
PALBOCICLIB, |
||||
| 294 | 25095946 |
CN |
35 | 2 |
Myelosuppression, |
||||
SACITUZUMAB GOVITECAN, LEUPROLIDE ACETATE, DENOSUMAB, |
||||
| 295 | 25095952 |
CN |
67 | |
Myelosuppression, |
||||
OLAPARIB, BEVACIZUMAB, |
||||
| 296 | 25095971 |
CN |
1 | |
Therapy partial responder, Myelosuppression, Marrow hyperplasia, Infection, |
||||
DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, PEGASPARGASE, PEGASPARGASE, PEGASPARGASE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, MERCAPTOPURINE, |
||||
| 297 | 25096036 |
CN |
4 | 1 |
Myelosuppression, White blood cell count decreased, Granulocyte count decreased, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 298 | 25096092 |
CN |
70 | 2 |
Myelosuppression, |
||||
CETUXIMAB, OXALIPLATIN, FLUOROURACIL, |
||||
| 299 | 25096109 |
CN |
||
Myelosuppression, COVID-19, Blood creatinine increased, |
||||
ABEMACICLIB, ABEMACICLIB, |
||||
| 300 | 25096181 |
CN |
57 | 2 |
Myelosuppression, |
||||
SACITUZUMAB GOVITECAN, SACITUZUMAB GOVITECAN, SACITUZUMAB GOVITECAN, SACITUZUMAB GOVITECAN, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28